What We're Reading: Page 181
Industry reads hand-picked by our editors
Apr 05, 2021
-
Science
Side effect worry grows for AstraZeneca vaccine
-
The Boston Globe
Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level
-
The Wall Street Journal
CEO Transformed Treatment for HIV, Hepatitis
Apr 01, 2021
Mar 31, 2021
-
The Wall Street Journal
Former Senior Merck Executive Hired by Life-Sciences Firm
-
The New York Times
Getting One Vaccine Is Good. How About Mix-and-Match?
-
Evaluate Vantage
Radiotherapeutics remain in the deal-making frame
-
Endpoints News
Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died
Mar 30, 2021
-
The Atlantic
A Terrible Conundrum for the AstraZeneca Vaccine
-
Endpoints News
After dismissing CFO over ‘inappropriate messages,’ Eli Lilly faces new accusations of sexual harassment
-
Axios
The growing fight over coronavirus vaccine patents
-
Reuters
Amarin's heart drug Vazkepa gets European Commission approval
Mar 29, 2021
-
ProPublica
Inside Purdue Pharma's Media Playbook: How It Planted the Opioid 'Anti-Story'
-
Science
A rare clotting disorder may cloud the world's hopes for AstraZeneca's COVID-19 vaccine
-
The Boston Globe
At Mass General Brigham, a sweeping effort to unify hospitals and shed old rivalries
-
CNBC
White House weighs temporarily lifting intellectual property shield on Covid-19 vaccines
-
Evaluate Vantage
Humanigen claims a Covid-19 win with lenzilumab
Mar 26, 2021
-
Bloomberg
Merck's Little Brown Pill Could Transform the Fight Against COVID
-
Fierce Pharma
Bristol Myers Squibb CEO Caforio collected $20M in 2020 pay
-
The New York Times
Executive With Ties to Cuomo Got Special Access to Virus Testing
-
Endpoints News
Two Church lab vets, a secretive institute and an Israeli billionaire hunt for drugs in the guts of wild animals
Mar 25, 2021
-
The Washington Post
NIH Moderna vaccine patent should be used to expand global access, advocates say
-
Evaluate Vantage
Big pharma's key catalysts in the second quarter
-
STAT
Companies helping big Covid-19 vaccine makers are getting rich
-
FiercePharma
Novartis is shutting down Colorado plant, laying off 400 employees after overestimating gene therapy demand
Previous
